Qu Biologics Begins Research McMaster University to Study New Crohn’s Disease

Qu Biologics

with to Study New Crohn’s Disease Research Model, VANCOUVER, BRITISH COLUMBIA We Need IDEAS Dec. 3, 2013 – Qu Biologics Inc., a biopharmaceutical business putting together Specific Immunomodulators (SSIs) that intend to induce the physical body’s invulnerable device versus autoimmune illness and cancer cells, revealed it is teaming up with to research a brand-new Crohn’s illness study model.

The partnership will certainly examine the efficiency of Qu Biologics’ Site Specific Immunomodulators (SSIs) to lessen intestinal tract irritation in an animal design of persistent E. coli infection. The research will certainly identify which sorts of invulnerable cells are linked with the resolution of irritation. McMaster University Associate Professor and Canada Research Chair, Dr. Brian Coombes, a microbiology specialist, will certainly look after the research. Dr. Coombes’ just recently released operate in Nature Communications shows that infection of computer mice with a pressure of Crohn’s connected adherent-invasive E. coli results in the advancement of digestive tract swelling in the computer mice which very closely appears like human Crohn’s illness. His group is now utilizing this analysis version as one which enables the research of Crohn’s condition in a persistent state.

Dr. Hal Gunn, CEO of Qu Biologics, commented, Dr. Brian Coombes’ current study is a crucial action to recognizing the source of Crohn’s condition. We delight in to be teaming up with Dr. Coombes’ analysis group and researching the prospective advantages of SSIs on Crohn’s illness.

Dr. Brian Coombes specified, We are really delighted to be participating in collective collaborate with Qu Biologics to research Site Specific Immunomodulators throughout persistent digestive tract infections. Adherent-invasive E. coli is a Crohn’s disease-associated microorganisms that has actually been reproducibly connecteded to human illness in many researches. As proof mounts for a microbial beginning of Crohn’s illness, comprehending the invulnerable feedback throughout persistent digestive tract infections develops brand-new chance for healing interferences.

About Dr. Brian Coombes
Dr. Brian Coombes is Associate Professor and Associate Chair in the Department of Biochemistry and Biomedical Sciences at McMaster University in Hamilton, Ontario. He is also the Assistant Dean, Graduate Education for the Faculty of Health Sciences. Dr. Coombes received his BSc in Biochemistry (1997) and his PhD in Medical Sciences (2002) from McMaster University. From 2002-2006 he was a CIHR and Michael Smith Foundation postdoctoral fellow at the University of British Columbia’s Michael Smith Laboratories in the lab of Dr. Brett Finlay, a world leader in microbial pathogenesis. In 2006, he joined the Department of Biochemistry & Biomedical Sciences where he runs an active research program in infectious diseases linked to acute and chronic gut infections. He currently holds a Canada Research Chair in Infectious Disease Pathogenesis and is the past recipient of the CIHR New Investigator Award (2007-2011), the Scientific Merit Award from the Public Health Agency of Canada (2007) the Boehringer Ingelheim Young Investigator Award (2010), the Fisher Scientific Prize (2012) and was inducted into Canada’s Top 40 Under 40 in 2010.

About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body’s immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and autoimmune disease. The company recently launched a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn’s disease.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO, Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease; and Chief Medical Officer, Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.
Qu Biologics Inc.
Julie Jang
Director, Communications
604.734.1450 ext.41491
[email protected]

Leave a Reply